CYYNF (Cynata Therapeutics) Institutional Ownership: 7.90% (As of Jul. 04, 2026)


What is Cynata Therapeutics Institutional Ownership?

Cynata Therapeutics CYYNF Institutional Ownership is 7.90% as of Jul. 04, 2026. The stock has 1 warning sign investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Cynata Therapeutics's institutional ownership is 7.90%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Cynata Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Cynata Therapeutics's Float Percentage Of Total Shares Outstanding is 0.00%.

Cynata Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Cynata Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cynata Therapeutics Institutional Ownership Chart

Cynata Therapeutics Historical Data

The historical data trend for Cynata Therapeutics can be seen below:

2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 9.15 9.16 9.17 9.17 9.18 9.18 9.18 9.18 9.09 9.09

Cynata Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 7.90% mean?
Cynata Therapeutics (CYYNF) has a Institutional Ownership of 7.90% as of Jul. 04, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Cynata Therapeutics and its competitors.
Is Cynata Therapeutics' Institutional Ownership too high?
Cynata Therapeutics' current Institutional Ownership is 7.90%.
How does Cynata Therapeutics' Institutional Ownership compare to VRTX and REGN?
Cynata Therapeutics' Institutional Ownership of 7.90% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Cynata Therapeutics and its competitors. Cynata Therapeutics's current Institutional Ownership is 7.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cynata Therapeutics stock overvalued right now?
Cynata Therapeutics (CYYNF) has a current Institutional Ownership of 7.90%. The current Institutional Ownership is 7.90%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Cynata Therapeutics (CYYNF), the current Institutional Ownership is 7.90% as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cynata Therapeutics Business Description

Other Exchanges 51S:GermanyCYP:Australia
Address 100 Cubitt Street, Level 3, Cremorne, VIC, AUS, 3121
Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus manufacturing platform. There are currently three active clinical trials taking place using Cymerus technology, which are attempting to treat osteoarthritis and others.